Therefore, in the current study we treated an EGFR/HER2-positive, hormone-independent AI-resistant breast cancer cell line with glyceollin + lapatinib to explore whether a more aggressive breast cancer subtype would be sensitive to combination therapy. Here, EGFR is linked to breast cancer.